dr. kahl on remaining challenges in indolent non-hodgkin lymphoma
Published 3 years ago • 426 plays • Length 1:25Download video MP4
Download video MP3
Similar videos
-
1:17
dr. kahl on treatment strategies for indolent lymphoma
-
1:42
dr. kahl on adct-402 for relapsed/refractory b-cell non-hodgkin lymphoma
-
1:31
dr. kahl on efficacy of targeted agents in relapsed/refractory indolent lymphomas
-
1:33
dr. kahl on the utility of tafasitamab/lenalidomide in dlbcl
-
2:03
dr. kahl on considerations for treatment strategies in cll
-
4:24
relapsed and refractory hodgkin lymphoma
-
2:57
challenges in the treatment of follicular lymphoma
-
0:54
dr. kahl on patient preference in treatment selection for cll
-
0:15
copy of dr. kahl on patient preference in treatment selection for cll
-
2:19
dr. kahl discusses polatuzumab vedotin in lymphoma
-
9:03
non-hodgkin’s lymphoma: exploring subtypes
-
1:35
dr. kahl on frontline therapy selection in cll
-
1:53
dr. kahl on frontline btk inhibitor selection in cll
-
2:02
dr. neelapu on updated zuma-1 findings in non-hodgkin lymphoma
-
1:07
dr. kahl discusses the potential of frontline ibrutinib in mcl
-
1:16
dr. brody on addressing resistance to immunotherapy in non-hodgkin lymphoma
-
1:05
dr. kahl on the current treatment landscape in relapsed/refractory inhl
-
0:57
dr. kahl discusses unmet needs in mcl
-
1:22
dr. jacobson on the safety profile of axi-cel in relapsed/refractory indolent lymphoma